Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Smoldering Multiple Myeloma 1Renal Insufficiency 1Multiple Myeloma 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × BHQ880 × Clear all
NCT01302886 2020-12-17

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Novartis

Phase 2 Completed
41 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT01337752 2020-12-17

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Novartis

Phase 2 Completed
9 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡